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Abstract
Background: Antidepressants (ADs) are commonly prescribed in primary care and are mostly indicated for
depression. According to the literature, they are now more frequently prescribed for health conditions other than
psychiatric ones. Due to their many indications in a wide range of medical fields, assessing the appropriateness of
AD prescription seems to be a challenge for GPs. The aim of this study was to review evidence from guidelines for
antidepressant prescription for non-psychiatric conditions in Primary Care (PC) settings.
Methods: Data were retrieved from French, English and US guideline databases. Guidelines or reviews were eligible
if keywords regarding 44 non-psychiatric conditions related to GPs’ prescription of ADs were encountered. After
excluding psychiatric and non-primary care conditions, the guidelines were checked for keywords related to AD
use. The latest updated version of the guidelines was kept. Recent data was searched in the Cochrane Database of
Systematic Reviews and in PubMed for updated reviews and randomized control trials (RCTs).
Results: Seventy-eight documents were retrieved and were used to assess the level of evidence of a potential benefit
to prescribing an AD. For 15 conditions, there was a consensus that prescribing an AD was beneficial. For 5 others, ADs
were seen as potentially beneficial. No proof of benefit was found for 15 conditions and proof of no benefit was found
for the last 9. There were higher levels of evidence for pain conditions, (neuropathic pain, diabetic painful neuropathy,
central neuropathic pain, migraine, tension-type headaches, and fibromyalgia) incontinence and irritable bowel
syndrome. There were difficulties in summarizing the data, due to a lack of information on the level of evidence, and
due to variations in efficacy between and among the various classes of ADs.
Conclusions: Prescription of ADs was found to be beneficial for many non-psychiatric health conditions regularly
encountered in PC settings. On the whole, the guidelines were heterogeneous, seemingly due to a lack of trials
assessing the role of ADs in treatment strategies.
Keywords: Antidepressants, Literature review, Therapeutic use, Family practice
Background
Antidepressants (ADs) are commonly prescribed in pri-
mary care (PC). Among the general population, the 12
month prevalence of ADs consumption ranges from 6%
to nearly 10% [1,2]. The main indications for ADs are
major depressive episodes and anxiety. Over the past 20
years, the use of ADs has grown extensively. Most
studies have shown a high level of consumption in all
industrialised countries. In France, between 1980 and
2008, AD sales increased sevenfold, from €84 million to
€525 million per year [3]. Selective Serotonin Reuptake
Inhibitors (SSRIs) and Selective Norepinephrine Re-
uptake Inhibitors (SNRIs) accounted for about 80% of
sales. Data in various industrialised countries showed
similar results [4-7]. In the United States, ADs are the
third most commonly prescribed medication [8,9]. This
growing prescription rate is a source of concern for
healthcare providers and healthcare economists alike
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[8,10]. The explanations for this high prescription rate
remain unclear, with little consensus, and the reasons
behind the phenomenon remain largely unknown
[11,12]. According to the literature, there are two main
causes for this situation. The first is over-prescription
for psychiatric conditions. Evidence does not show ADs
to be highly clinically effective in treating moderate de-
pression, which is frequently encountered in PC settings,
although several recent studies have found that ADs
could possibly be beneficial in treating milder episodes
[13,14]. ADs are sometimes discontinued too early or
prescribed too long [15,16]. Assessing the potential
benefit of AD prescription seems to be a challenge, as
the variations in measurement specifications in the stud-
ies impact the conclusions that are drawn about treat-
ment of depression [17]. The second reason is the
prescription of ADs for “non-psychiatric conditions”.
Growing evidence points to ADs being frequently pre-
scribed for conditions or health problems outside the
field of psychiatry [18]. Some observational data suggest
that this proportion varies between 25% and 60%
[19,20]. Exploratory research has confirmed that GPs
prescribe ADs for many non-psychiatric conditions and
off-label uses. In many fields, GPs used their feelings
and feelings on the products’ efficacy rather than scien-
tific evidence to prescribe. [21]. The aim of this study
was to review the level of evidence for the prescription
for ADs in non-psychiatric PC conditions in order to
help GPs in their daily practice.
Methods
The overall review process is summarised in Figure 1.
Defining the limits of the searches
To retrieve the level of evidence for the prescription of
ADs in non-psychiatric PC settings, an initial search was
performed using the MeSH terms for the 24 medical
conditions collected in our previous qualitative study
and the terms “antidepressants” and “therapeutic use” in
PubMed [21]. During this process, 30 additional condi-
tions possibly leading to AD prescription were found
resulting in a list of 54 conditions or medical circum-
stances for which ADs could possibly be prescribed. Ten
conditions - psychiatric disorders, non-primary care and
non-adult conditions - were then excluded: five purely
psychiatric disorders, narcolepsy and myotonia because of
their low prevalence in primary care, nocturnal enuresis
as a paediatric condition and amphetamine withdrawal
and cocain dependence being conditions to be managed
in multidisciplinary and specialised environment. This
process resulted in a list of 44 non-psychiatric disorders
manageable in PC and potentially leading to AD prescrip-
tion in PC (Table 1). This list was used for the data collec-
tion search strategy.
Data collection: search strategy
The terms matching with the 44 conditions and medical
circumstances for possible AD prescription were listed
in French and English. The MeSH validated translation
Figure 1 Methods and overall process. (a) Conditions mentioned by the GPs ref. (b) Conditions collected via Pubmed searches. (c) Guidelines
before 1997, paediatrics, nursing practices, patient information or education, medical records, continuous medical education for care providers,
medical imaging, biology and surgical techniques. (d) Selection of the latest guidelines containing the key words (antidepressant”, “Tricyclic
agents”, “TCA”, “SNRI”, “serotonin”, “SSRI”, “tricyclic”, “imipramine”, “monoamine”, “duloxetine”, “venlafaxine).
Mercier et al. BMC Family Practice 2013, 14:55 Page 2 of 10
http://www.biomedcentral.com/1471-2296/14/55
and synonyms were searched for in the terminology sec-
tion of the catalogue and index of the French-language
Health Resources Website (CISMeF). When there was
no MeSH term available for the medical condition or
circumstance, the researchers used a broader MeSH
term, on a higher level of hierarchy, including the de-
scription (e.g., cancer AND antidepressants for “cancer
related fatigue, musculoskeletal diseases AND antide-
pressants for musculoskeletal symptoms). Using this list,
searches were performed to find the available guidelines
(GL) in the databases of the following government agen-
cies: the French “Haute Autorité de Santé” (HAS), the
English National Institute for Clinical Excellence (NICE)
and the National Guideline Clearinghouse (NGC), the
last one including most international guidelines. The
searches were performed from March 2011 to August
2011. The search covered all of the documents made
available by the three agencies.
Data collection: additional searches for updated data
During the same period, we performed simultaneously, a
search in the Cochrane database of systematic reviews
(CDSR) and in Medline on the same basis, using the
same criteria and process. For the Medline search, the
following limits were used: “clinical trial, meta-analysis,
clinical guidelines, randomized controlled trial, and
adults, published after 2004”. The aim was to find scien-
tific data published after the launch of the guidelines.
Those studies might change the evidence and possibly
lead to a change in prescription attitudes. All detailed
searches are available in the full version of all guidelines.
Individual studies (RCTs in Pubmed) included in this re-
view did not constitute the bulk of the results.
Data extraction
All guidelines before 1997 were excluded, as were those
regarding paediatrics, nursing practices, patient informa-
tion or education, medical records, continuing medical
education for care providers, medical imaging, biology
and surgical techniques. Full text of guidelines have been
downloaded from the agencies databases. All non-
psychiatric conditions were included and all standalone
psychiatric conditions were excluded. Remaining docu-
ments on anxiety, depression and side effects of ADs
were also excluded after reading. The documents were
independently read and assessed by two researchers
(AM & IAA) and disagreements were resolved by dis-
cussion. Duplicates were removed. The documents in
the databases were crosschecked using a search with the
generic term “antidepressants” in order to retrieve any
documents that may have been missed by previous
searches. In the full text documents, the terms “anti-
depressant”, “Tricyclic agents”, “TCA”, “SNRI”, “sero-
tonin”, “SSRI”, “tricyclic”, “imipramine”, “monoamine”,
“duloxetine”, “venlafaxine” and their French translations
were searched for. All guidelines containing the key-
Table 1 Conditions included and excluded in the searches
Conditions included: primary care,
non-psychiatric n = 44
Pain: n = 14
Neuropathic pain, diabetic painful neuropathy, HIV-related neuropathy, trigeminal neuralgia, post herpetic
neuralgia, phantom limb pain, central neuropathic pain, burning mouth syndrome, migraine, tension-type
headaches (with or without drug abuse), fibromyalgia, non-specific low back pain, sciatica
Other neurological conditions or symptoms: n = 9
Dementia (agitation), Parkinson’s disease (depression / agitation), emotionalism after stroke, prevention of
depression after stroke, motor recovery after ischemic stroke, sleep disorders, restless legs syndrome, sialorrhea,
tinnitus
Urological conditions: n = 5
Urinary incontinence, overactive bladder syndrome, urinary stress incontinence, erectile dysfunction, premature
ejaculation
Dependence: n = 2
Smoking cessation, alcoholism
General or non-specific conditions, general symptoms: n = 10
“Chronic fatigue Syndrome or Asthenia or Fatigue”, cancer-related fatigue, depression in physically ill people,
musculoskeletal symptoms, unexplained complaints, somatoform disorders, treatment refusal, patient
compliance, weight loss in adults with type 2 diabetes mellitus, pruritus
Gynaecological conditions: n = 3
Premenstrual syndrome, hot flashes/drug therapy, menopause
Gastroenterological conditions: n = 1
Functional colonic diseases: irritable bowel syndrome
Conditions excluded: 1 n = 10 Narcolepsy, anorexia nervosa, isolated depression, dysthymic disorder, all isolated anxiety conditions, bulimia
nervosa, amphetamine withdrawal, nocturnal enuresis, myotonia, cocaine dependence
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words were selected. In order to find the latest evidence,
the most recent documents available on each topic in
each guideline database were retained when available,
and the most up-to-date version of the selected guide-
lines was kept. The overall process ended with a list of
78 documents.
Critical assessment
The final stage of the study aimed to retrieve guidelines
on recommended therapeutic use of ADs from these
documents. Sections of specific interest were extracted
and analysed. Information on pharmaceutical classes,
drugs, recommended therapeutic use and level of evi-
dence was collected when available. Agreements and dis-
cordances were noted, and inconsistencies between the
various guidelines were highlighted. Recommendations
from the guidelines were graded according to the EFNS
scheme [22] (Additional file 1).
Results
We collected 1,325 documents on 44 conditions. After
exclusion, 141 remained. After applying our criteria for
data extraction, 78 documents were retrieved, including
36 GLs, 38 reviews or systematic reviews (some followed
by a meta-analysis) and 4 RCTs. The guidelines enabled
us to describe the evidence for AD prescription for 27
conditions. For 14 conditions, searches in CDSR and
PubMed retrieved updated information. For 3 conditions
(somatoform disorders, treatment refusal, and patient
compliance), no data were found. Among the 44 condi-
tions, ADs were found to be potentially beneficial with a
high level of evidence in treating 15 conditions and po-
tentially beneficial with a lower level of evidence in
treating 5 others. No proof of benefit was found for 15
conditions and proof of no benefit for 9. All results are
detailed in Table 2.
Pain conditions
All results for pain conditions are described in Table 3.
Neurological conditions
The guidelines, reviews and RCTs found prescription
of sertraline, citalopram and trazodone to be poten-
tially beneficial in treating behavioural perturbations,
mood disorders and agitation in patients with demen-
tia, though no level of evidence was available [40,41].
Potential side effects and difficulty in managing the
prescription were emphasised [42]. ADs were found to
have no specific effects in treating Parkinson’s disease,
apart from those in treating its associated psychiatric
indications [43].
Concerning stroke, three kinds of problems were
assessed: treatment of emotionalism, prevention of de-
pression and the benefit of prescribing an AD in the
acute stage to facilitate recovery of motor skills. ADs
were recommended for emotional instability (Level B)
[44,45]. They reduced the frequency and severity of cry-
ing and laughing episodes. The effect did not seem
Table 2 Assessment of AD usefulness
-Neuropathic pain (neuralgia and painful polyneuropathy), diabetic painful neuropathy, central neuropathic pain, migraine,
tension-type headaches, fibromyalgia
Useful (1) -Urinary stress incontinence, premature ejaculation
n = 15 -Prevention of depression after stroke, emotionalism after stroke -Smoking cessation
-Premenstrual syndrome, hot flashes/drug therapy, hot flashes during menopause
-Irritable bowel syndrome
Possibly useful (2) -Post herpetic neuralgia, trigeminal neuralgia
n = 5 -Agitation in dementia, motor recovery after ischemic stroke
-Overactive bladder syndrome
No proof of
benefit (3)
- Tension-type headaches with drug abuse, sciatica, Parkinson’s disease, sleep disorders
n = 15 - pruritus
- Asthenia- fatigue-chronic fatigue syndrome, cancer-related fatigue, depression in physically ill people
- Unexplained complaints, somatoform disorders, treatment refusal, patient compliance, weight loss in adults with
type 2 diabetes
Proof of no
benefit (4)
-HIV related neuropathy, phantom limb pain, burning mouth syndrome, non-specific low back pain, restless legs syndrome
n = 9 -Other urinary incontinence conditions, erectile dysfunction -Alcoholism /
alcohol misuse
-Musculoskeletal symptoms (5)
(1) Recommended with evidence level mentioned or recent meta-analysis. (2) Mentioned without level of evidence, or second line treatment, or only RCTs. (3) Not
enough or no data, apart from psychiatric condition. (4) No benefit mentioned in RCTs or reviews. (5) See fibromyalgia in Table 3.
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Table 3 ADs in pain conditions 1
Condition AD treatment, role in strategy, rating of the
recommendation
Comments and role of other treatments
Neuralgia and
painful
polyneuropathy
[22-26]
ADs recommended: -Similar statements between guidelines:
-TCAs: Amitriptyline first line (25–150 mg/day, Level A)
Nortriptyline (alternative option) [22-26] NNT of 3.6 (95% CI: 3-4.5).
-Strong consensus for TCAs and venlafaxine.
-SNRIs: Venlafaxine, fist line treatment (Level A) NNT of 3.1
Duloxetine: option
-Gabapentin, Pregabalin: also recommended as first-line
treatments. TCAs are equally effective compared to non-AD
drugs gabapentin (1200–3600 mg/day) and pregabalin (150–
600 mg/day)SSRI: not recommended
Painful Diabetic
Neuropathy (PDN)
[25-29]
ADs recommended:
-Duloxetine 60 mg and 120 mg daily, first-line, (Level A) The
NNT for effectiveness was 1.3 (95% CI: 1.2- 1.5). This AD has
on-label use for this condition [25,26,28]
Duloxetine: conflicting evidence between guidelines, just
cited as a therapy for NP in the EFNS GL[24], and only for
PDN in the Cochrane Review
-Venlafaxine 150–225 mg/day; first line (no level mentioned)
TCA : If other ADs contraindicated, Amitriptyline is an option Venlafaxine might be added to gabapentin for a better
response (Level C).
SSRIs: not recommended
HIV-related
neuropathies [27]
No AD treatment recommended
-Evidence not to prescribe any AD
- Recommended non-AD treatments: -lamotrigine (Level B),
smoking cannabis (Level A), capsaicin patches (Level A)
Phantom limb
pain [30]
No AD treatment recommended Amitriptyline was not different from placebo
Trigeminal
neuralgia [25,26]
-ADs are not first-line treatment
-Similar statements but lack of comparative trials to assess a
precise role for TCAs and venlafaxine.
-ADs recommended: TCA or venlafaxine are alternative
treatments
First-line: carbamazepine (Level A) and oxcarbazepine (Level B)
Postherpetic
neuralgia [25,26]
-ADs are not first-line treatments -Similar statements but lack of comparative trials to assess a
precise role for TCAs and venlafaxine
- ADs recommended: TCA or venlafaxine are alternative
treatments
-First-line: gabapentin / pregabalin (Level A)
Central pain 2 [24] -ADs are not first-line treatment -Similar statements between guidelines
- ADs recommended: TCAs: Amitriptyline second-line (Level B)-
SNRIs: Duloxetine and venlafaxine second choice (Level B)
-Pregabalin: first-line (level A)
Migraine and
tension type
headaches [31-34]
ADs recommended: -Similar statements for TCAs, and SSRIs. Disagreement for the
usefulness of venlafaxine
-TCA: Amitryptiline 25-150 mg per day, (Level A).-Venlafaxine
75-150 mg was presented as an effective alternative to
tricyclic antidepressants (Level B)
-TCA: In cases of TTH with associated drug abuse, the role of
this treatment was only mentioned, with no rating, by the
French HAS.
SSRIs: not recommended
Sciatica, non-specific
low back pain
[35-37]
No AD treatments recommended Only to be prescribed as an option in the event of associated
depression (NICE)
Very weak evidence for TCAs observed by the French HAS
(level C)
Fibromyalgia3 [28,38] ADs recommended: Alternative pharmacological options: Gabapentin, tramadol
SNRIs: Milnacipran 12.5 mg once daily, target dose of 50-100
mg two times per day
-Duloxetine: 60 mg twice daily, -Venlafaxine could be
prescribed -TCAs showed evidence
SSRIs: not recommended
Burning mouth
syndrome [39]
No AD treatments recommended -Two RCTs showed no antidepressant effects
(1) Neuropathic pain is related to different treatment strategies and different conditions detailed in this table.
(2) Diffuse pain, refractory or recurrent pain, central pain, pain connected with multiple sclerosis, dysesthesia after stroke or paraplegia.
(3) See also comments in plain text: General or non-specific conditions and general symptoms.
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specific to one drug or class of drugs. Early prescription
prevented depression, but no improvement in its severity
was found when depression was actually occurring [46].
Early prescription of fluoxetine with physiotherapy
found that patients with ischemic stroke and moderate
to severe motor deficit could enhance motor recovery
after 3 months [47].
Antidepressants were found to provide no benefit in
treating isolated sleeping disorders and primary insom-
nia even though they were found to be potentially bene-
ficial in the event of psychiatric comorbidity [48].
Antidepressants were not recommended for use in cases
of restless legs syndrome, which was in fact presented as a
side effect of ADs [49].
As well, there was no evidence of a benefit in prescribing
ADs for cases of sialorrhea related to neurological condi-
tions (Amyotrophic lateral sclerosis (ALS), Parkinson’s dis-
ease), although prescription was sometimes recommended
[50]. Antidepressants were found to have no proof of
benefit for cases of tinnitus [51].
Urological and gynaecological conditions
Duloxetine was found to have potential benefits as a
second-line (Level C) treatment for patients with stress
urinary incontinence. Duloxetine significantly improved
quality of life but TCAs did not. Anticholinergic agents,
such as TCAs, were found to have potential benefits for
patients with overactive bladder syndrome [52-54]. Proof
of benefit was observed for incontinence caused by other
urological conditions. Antidepressants were cited as a
potential source of side effects for these conditions [55].
One Cochrane review attested that all SSRIs were
highly effective in reducing symptoms related to severe
premenstrual syndrome, (also called pre-menstrual dys-
phoric disorder or luteal phase dysphoric disorder)
(SMD -0.53, 95% CI: 0.68 to -0.39; P < 0.00001) with no
level of evidence available [56]. Another Cochrane re-
view reported that SSRIs and SNRIs had a mild to mod-
erate effect in reducing hot flashes during menopause in
women with a history of breast cancer, as well as in men
with a history of prostate cancer (Level B) [57].
SSRIs were not recommended for erectile dysfunction.
They were, however, recommended as a first-line (Level A)
treatment for premature ejaculation [58,59].
Dependence
Nortriptyline was shown to be effective for tobacco
withdrawal (OR 2.79 (95% CI: 1.70-4.59) whereas moclo-
bemide, venlafaxine and SSRIs did not show any ef-
fectiveness (no level of evidence available) [60]. All
guidelines and reviews agreed that ADs were not indi-
cated for alcohol misuse or dependence [61]. It is clearly
stated that depression is a direct consequence of alcohol
abuse, and that AD prescription is useless if the patient
does not stop drinking.
General or non-specific conditions and general symptoms
The term “fatigue” pooled together a wide variety of
health problems. No data was retrieved for isolated fa-
tigue. In the NICE guideline, ADs were not found to be
beneficial in treating chronic fatigue syndrome. ADs
were considered as useless for cancer-related fatigue but
beneficial in treating depression related to purely physi-
cal conditions, with no effect on the physical conditions
themselves [62].
Prescribing an AD provided no benefit for musculo-
skeletal symptoms, except for fibromyalgia, which is
assessed in the “pain conditions” section of the results
(see also Table 3) [63]. No data was retrieved regarding
prescription for unexplained complaints, somatoform
disorders, treatment refusal, chronic pruritus, helping
type 2 diabetes patients to lose weight, and improving
medical adherence or patient compliance.
Gastroenterological conditions
According to the CDSR, TCAs could be used as a
second-line treatment and SSRIs as a third-line treat-
ment, for irritable bowel syndrome (IBS) (no level of
evidence available) [64,65].
Discussion
Summary of the main results
Antidepressants were found to be potentially useful with
a high level of evidence for 15 conditions and potentially
useful with a lower level of evidence for 5 others. Pre-
scribing an AD was found to be potentially beneficial for
patients with many pain conditions as well as urologi-
cal, gastroenterological and gynaecological conditions.
Nevertheless, while prescribing, the GP has to refer to
on-label use for his own country, because unfortunately,
proof of benefit is not related to “on label use”. The evi-
dence reviewed provided insufficient support for pre-
scribing ADs for 24 other conditions. Restless legs
syndrome, non-specific urinary incontinence and erectile
dysfunction exposed in the “proof of no benefit” section
were side effects of ADs. For rheumatologic conditions,
(musculoskeletal symptoms and non-specific low back
pain) the “proof of no benefit” should be interpreted
with caution, due to the difficulty in assessing these
patients in a primary care setting. Pain symptoms or
somatoform complaints may be similar to those encoun-
tered in fibromyalgia, a clinical syndrome that lacks a
clear definition and is still a subject of debate [66]. For
the other 15 conditions listed in the “No proof of bene-
fit” section, this should be understood as “having no spe-
cific effect on the non-psychiatric condition mentioned”.
For example, no guidelines found ADs to have a specific
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effect in treating Parkinson’s disease comparable to their
effect in treating dementia-related agitation. Neverthe-
less, ADs should be prescribed in the event of a major
depressive episode related to Parkinson. The same can
be said for treating depression in physically ill people or
those with cancer [62]. Thus, an AD considered as ha-
ving no specific benefit for a given condition may prove
beneficial for certain specific PC patients. As a result, it is
difficult for prescribing physicians to assess the potential
benefit of using them in clinical practice in PC settings
where several conditions are involved.
Strengths and limitations of the study
The first strength of the study was the meticulous meth-
odology and careful step-by-step process used to extract
the data. The analysis was not started from a theoretical
framework, but from real daily practice in primary care,
based on the qualitative material of our previous research
[21]. No previous study has assessed in that way the ap-
propriateness of AD prescriptions for non-psychiatric
conditions. This review gives a new insight on studies em-
phasizing misuse as an explanation for the increasing rate
of AD prescription [67-70]. A second strength was that it
provided all GPs a clear overview of information on ADs
not limited to the information and guidelines available in
their own country. Finally, a third strength of the study
was that it updated the guidelines with recent reviews, in
order not to miss relevant information. This study, being
an analysis of guidelines and systematic reviews did not
focus on a single condition, population or intervention,
but on a family of drug (ADs) and their indications. Thus,
the nature of this analysis made it impossible to perform a
systematic review fulfilling the “Prisma” statements. An-
other limitation of this study was the consistency of the
available data. First of all, levels of evidence were not al-
ways available. When available, levels of evidence were not
always consistent between the different guidelines, as was
the case with diabetic painful neuropathy. Additionally,
either a given AD, only certain ADs or an entire class of
ADs could be considered as having a potential benefit in
treating a specific condition. For example, among the
SSRIs, only citalopram and sertraline were assessed in
treating dementia-related agitation. Also, the optimum do-
sage to be used in treating a condition was not always
determined, as in the case of using amitryptiline to treat
migraine or neuropathic pain. Finally a limitation of our
study could be that some guidelines in other languages than
French and English were not selected in the search. How-
ever we used the big databases such as Medline and NGC,
which already include guidelines, sometimes translated in
English, from many guideline developers worldwide.
Performing a strict assessment and comparison of se-
veral conditions appeared arduous: although the subjects
of the recommendations were similar, the guidelines did
not refer to strictly comparable conditions. For example
difficulties were encountered with fibromyalgia, chronic
fatigue syndrome and rheumatologic pain, which were
difficult to distinguish from one another. This lack of
precision can lead to difficulties in assessing and summa-
rizing information, and consequently in correctly under-
standing the potential benefit of ADs for patients. As well,
the randomised trials were designed for well-defined con-
ditions and homogeneous populations, which is rarely the
case for PC patients. The inclusion criteria for the studies
often involved secondary care and did not reflect primary
care situations.
The limitations of available data and the wide variety
of conditions made it difficult to formulate clear recom-
mendations. In any case, the results of the study provide
new insight to enable clinicians to prescribe ADs with
more accuracy, and could potentially serve as a point of
reference for health policy organizations in specifying
prescription rules.
Consistency of GPs’ prescriptions with the evidence
Comparing the 24 non-psychiatric health conditions for
which the GPs claimed to prescribe ADs [21] with the re-
sults of this review study, 12 conditions were found to be
based on evidence. Of the 12 other conditions for which
GPs claimed a prescription of an AD, there was no scien-
tific evidence. In our qualitative study, the GPs correctly
assessed the benefit of ADs in treating pain conditions
[21]. This seems contradictory with observational studies
finding that pain management could be improved in PC
settings [71]. However GPs’ proper assessment of the
benefit of ADs, depends on his ability to make a fine dis-
tinction between “the scientifically proven effect of an AD
for a certain condition” and “the potential benefit of an
AD at the right dose for a specific patient presenting with
several psychiatric or non-psychiatric conditions”. Besides
the GP’s decision is based not only on biomedical observa-
tions, but also follows a bio-psychosocial model in which
patient-centeredness and the environment are taken into
account [67]. The major benefit of this study is to under-
stand better and justify GPs’AD prescription behaviour.
Implications for future research
On the whole, the guideline agencies often stressed a
lack of head-to-head comparative trials assessing the
clinical effectiveness of the drugs, which would allow
physicians to prioritise the choice of therapy for a given
condition. This is impossible without any involvement
from healthcare institutions. Another challenge is to bet-
ter understand the way physicians prescribe ADs in ac-
tual PC settings. We currently know that GPs’ decisions
are shaped by a combination of diseases and psycho-
social influences. The potential benefit of a prescription
for a patient cannot be assessed without incorporating
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all of the dimensions of actual prescription. This re-
quires a strict comparison that directly assesses the pre-
scriptions, indications and patients’ environment, based
on observational cohort studies to collect data on medi-
cal conditions, psychosocial environment and prescrip-
tions in PC settings.
Conclusions
Prescription of ADs was found to be useful for many
non-psychiatric health conditions commonly encoun-
tered in primary care. Evidence against prescribing ADs
was also found. The overall inconsistency of available in-
formation hindered precise assessment of the evidence.
There remains much uncertainty as regards the role of
prescribing ADs in therapeutic strategies, as well as the
appropriateness and accuracy AD prescriptions. It is im-
portant to emphasise the difference between assessing
the scientifically proven effect of an AD for a certain
condition and the potential benefit of an AD at the right
dose for a specific patient despite a lower level of evi-
dence. Further studies are required to provide physicians
more comprehensive knowledge and to improve patient
care.
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